Fukuda R, Tokuda A, Kohge N, Xuan N T, Uchida Y, Akagi S, Fukumoto S
2nd Department of Internal Medicine, Shimane Medical University.
Nihon Shokakibyo Gakkai Zasshi. 1993 Sep;90(9):2103-10.
Duck hepatitis B virus (DHBV) carrier ducks of one week old were injected with Ara-A (adenine arabinoside) of different dose including 2.5 (11 ducks), 5.0 (11), 10.0 (10) and 20.0 (10) mg/kg for 14 days. This antiviral effect showed dose-dependence up to 5.0 mg/kg and this dose seemed effective to obtain significant antiviral effect. Viral DNA and DNA polymerase activity were reduced significantly from the 1st week after starting the administration of Ara-A. This antiviral effect was maintained even at the 1st week after discontinuation of the drug. These findings were quite similar to those observed in HBV carriers. With the increasing necessity of Ara-A treatment in patients who will not respond to interferon therapy, DHBV seemed a suitable model for the investigation of the dose and antiviral effect of Ara-A treatment in humans.
给一周龄的鸭乙型肝炎病毒（DHBV）携带鸭注射不同剂量的阿糖腺苷（Ara - A），剂量分别为2.5（11只鸭）、5.0（11只）、10.0（10只）和20.0（10只）mg/kg，持续14天。在高达5.0 mg/kg时，这种抗病毒作用呈现剂量依赖性，且该剂量似乎能有效获得显著的抗病毒效果。从开始给予Ara - A后的第1周起，病毒DNA和DNA聚合酶活性显著降低。即使在停药后的第1周，这种抗病毒作用仍得以维持。这些发现与在HBV携带者中观察到的结果非常相似。鉴于对干扰素治疗无反应的患者对Ara - A治疗的需求日益增加，DHBV似乎是研究Ara - A治疗在人类中的剂量和抗病毒效果的合适模型。
